Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study
- PMID: 33033142
- DOI: 10.1158/1055-9965.EPI-20-0735
Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study
Abstract
Background: Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) of the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with the long-term risk of CNS SPN, and quantified the dose-response relationships.
Methods: We selected all CNS SPN cases diagnosed up to 2016 among members of the French Childhood Cancer Survivor Study at least 5 years after first cancer diagnosis in 1946-2000. Four controls per case were randomly selected within the cohort and matched by sex, year of/age at first cancer diagnosis, and follow-up time. On the basis of medical and radiological reports, cumulative radiation doses received to the SPN or matched location were retrospectively estimated using mathematical phantoms. We computed conditional logistic regression models.
Results: Meningioma risk significantly increased with higher radiation doses [excess OR per Gy (EOR/Gy) = 1.377; P < 0.001; 86 cases; median latency time = 30 years], after adjustment for reported genetic syndromes and first CNS tumor. It was higher among youngest individuals at first cancer diagnosis, but did not vary with follow-up time. On the opposite, radiation-related glioma risk (EOR/Gy = 0.049; P = 0.11; 47 cases; median latency time = 17 years) decreased over time (P for time effect = 0.05). There was a significant association between meningioma risk and cumulative doses of alkylating agents, but no association with growth hormone therapy.
Conclusions: The surveillance of patients with cranial irradiation should continue beyond 30 years after treatment.
Impact: The identified risk factors may inform long-term surveillance strategies.
©2020 American Association for Cancer Research.
Similar articles
-
New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37. doi: 10.1093/jnci/djj411. J Natl Cancer Inst. 2006. PMID: 17077355
-
Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.J Clin Oncol. 2010 Dec 20;28(36):5287-93. doi: 10.1200/JCO.2009.27.0090. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079138 Free PMC article.
-
Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review.Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):640-654. doi: 10.1016/j.ijrobp.2023.07.025. Epub 2023 Sep 29. Int J Radiat Oncol Biol Phys. 2024. PMID: 37777927
-
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.J Natl Cancer Inst. 2009 Jul 1;101(13):946-58. doi: 10.1093/jnci/djp148. Epub 2009 Jun 17. J Natl Cancer Inst. 2009. PMID: 19535780 Free PMC article.
-
Risk and survival outcomes of radiation-induced CNS tumors.J Neurooncol. 2016 Aug;129(1):15-22. doi: 10.1007/s11060-016-2148-3. Epub 2016 May 21. J Neurooncol. 2016. PMID: 27209188 Review.
Cited by
-
Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors.Front Endocrinol (Lausanne). 2021 Oct 22;12:745932. doi: 10.3389/fendo.2021.745932. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34745010 Free PMC article. Review.
-
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.Br J Cancer. 2024 Apr;130(6):976-986. doi: 10.1038/s41416-024-02577-y. Epub 2024 Jan 19. Br J Cancer. 2024. PMID: 38243010 Free PMC article.
-
Dosiomics-Based Prediction of Radiation-Induced Valvulopathy after Childhood Cancer.Cancers (Basel). 2023 Jun 8;15(12):3107. doi: 10.3390/cancers15123107. Cancers (Basel). 2023. PMID: 37370717 Free PMC article.
-
Neurological hospitalisations in childhood cancer survivors treated before 2001: findings from the French Childhood Cancer Survivor Study cohort.BMC Neurol. 2024 Sep 10;24(1):335. doi: 10.1186/s12883-024-03797-8. BMC Neurol. 2024. PMID: 39256648 Free PMC article.
-
Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer.J Natl Cancer Inst. 2025 May 1;117(5):1036-1045. doi: 10.1093/jnci/djaf005. J Natl Cancer Inst. 2025. PMID: 39792043
References
-
- Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–31.
-
- Hewitt M, Weiner SL, Simone JV. Childhood cancer survivorship: improving care and quality of life. 2003.
-
- Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218–27.
-
- Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:5287–93.
-
- Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528–37.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical